<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27216" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pigmented Villonodular Synovitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fecek</surname>
            <given-names>Christopher</given-names>
          </name>
          <aff>Peconic Bay Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Carter</surname>
            <given-names>Kevin R.</given-names>
          </name>
          <aff>McLaren Oakland</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Christopher Fecek declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kevin Carter declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27216.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Pigmented villonodular synovitis (PVNS) refers to a subtype of tenosynovial giant cell tumors that diffusely affect the soft tissue lining of joints and tendons. PVNS most commonly affects the knee, hip, and ankle joints and is insidious in onset, with symptoms often being present for years before diagnosis. This activity outlines the evaluation of pigmented villonodular synovitis and highlights the role of the inter-professional team in improving care for patients with this condition. Additionally, this activity illustrates the treatment of pigmented villonodular synovitis and explains the role of the healthcare team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the patient history associated with pigmented villonodular synovitis.</p></list-item><list-item><p>Identify the physical exam findings associated with pigmented villonodular synovitis.</p></list-item><list-item><p>Describe the imaging findings associated with pigmented villonodular synovitis.</p></list-item><list-item><p>Summarize the importance of collaboration and communication amongst the interprofessional team to improve outcomes for patients affected by pigmented villonodular synovitis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27216&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27216">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27216.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Pigmented villonodular synovitis (PVNS) refers to a subtype of tenosynovial giant cell tumors that diffusely affect the soft tissue lining of joints and tendons.&#x000a0;&#x000a0;PVNS most commonly affects the knee, hip, and ankle joints and is insidious in onset, with symptoms often being present for years before diagnosis.<xref ref-type="bibr" rid="article-27216.r1">[1]</xref><xref ref-type="bibr" rid="article-27216.r2">[2]</xref> Furthermore, PVNS is more aggressive compared to the other major subtype of tenosynovial giant cell tumors, giant cell tumor of the tendon sheath (GCT-TS).&#x000a0;&#x000a0;According to a 1980 report, PVNS affects roughly 9.2 new people per million in the United States each year.<xref ref-type="bibr" rid="article-27216.r1">[1]</xref> Even after treatment, the recurrence rate of PVNS ranges from 14 to 55%.<xref ref-type="bibr" rid="article-27216.r2">[2]</xref></p>
      </sec>
      <sec id="article-27216.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Pigmented villonodular synovitis has been shown to have neoplastic components. Translocations of chromosome 1p13 are present in the majority of PVNS cases with the endpoint effect of overexpressing colony-stimulating factor 1 (CSF1). As CSF-1 becomes overexpressed, clusters of aberrant cells form to create focal areas of soft tissue hyperplasia in the synovial cells lining joints.<xref ref-type="bibr" rid="article-27216.r3">[3]</xref></p>
      </sec>
      <sec id="article-27216.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Due to its slow onset, the median time of definitive diagnosis from the onset of symptoms to definitive diagnosis has been shown to be 18 months.<xref ref-type="bibr" rid="article-27216.r4">[4]</xref> There is conflicting data regarding the gender distribution of pigmented villonodular synovitis. Some studies suggest that male and female genders are affected at equal rates,<xref ref-type="bibr" rid="article-27216.r3">[3]</xref> while others suggest females are slightly more predisposed, but only in the context of localized disease.<xref ref-type="bibr" rid="article-27216.r5">[5]</xref><xref ref-type="bibr" rid="article-27216.r6">[6]</xref> Pigmented villonodular synovitis has been consistently shown to have a lower incidence in pediatric populations. As a result, it gets more frequently misdiagnosed in children.<xref ref-type="bibr" rid="article-27216.r7">[7]</xref></p>
      </sec>
      <sec id="article-27216.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Synovial fluid analysis in pigmented villonodular synovitis most often has a dark brown or hemorrhagic color.<xref ref-type="bibr" rid="article-27216.r8">[8]</xref> Microscopic workup reveals an assortment of mononuclear cells, macrophages with extensive hemosiderin stores, and multinucleated osteoclast-type giant cells.<xref ref-type="bibr" rid="article-27216.r9">[9]</xref> Specifically, hemosiderin deposits result from the episodic nature of the disease. As repeated bleeding into the joint occurs, hemoglobin breaks down to form large deposits of iron in surrounding tissues. The resulting hemosiderin-laden parenchyma is a direct reflection of recurrent hemarthrosis in patients with PVNS.<xref ref-type="bibr" rid="article-27216.r8">[8]</xref><xref ref-type="bibr" rid="article-27216.r10">[10]</xref></p>
      </sec>
      <sec id="article-27216.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The tumor of pigmented villonodular synovitis is slow-growing, and, early on in the disease course, the patient presents with unexplained painless swelling in the affected joint.<xref ref-type="bibr" rid="article-27216.r6">[6]</xref> As the tumor expands, however, pain and swelling add to cause moderate to severe range of motion&#x000a0;limitations in the affected area.<xref ref-type="bibr" rid="article-27216.r6">[6]</xref><xref ref-type="bibr" rid="article-27216.r9">[9]</xref> As the disease progresses, recurrent hemarthrosis leads to worsening joint stiffness and moderate to severe joint destruction.<xref ref-type="bibr" rid="article-27216.r11">[11]</xref> A single joint presentation is the most common, but rarely PVNS can present polyarthropically.<xref ref-type="bibr" rid="article-27216.r7">[7]</xref> Since the onset of symptoms in PVNS is insidious, patient history often includes an extensive workup for other causes of joint pain.<xref ref-type="bibr" rid="article-27216.r12">[12]</xref> Pigmented villonodular synovitis typically occurs in the large joint of the upper and lower extremities. Most commonly, the disease affects the knee in the&#x000a0;patellofemoral compartment&#x000a0;at the&#x000a0;infrapatellar fat pad.<xref ref-type="bibr" rid="article-27216.r6">[6]</xref></p>
      </sec>
      <sec id="article-27216.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Clinicians typically pigmented villonodular synovitis through a combination of several radiographic modalities. Initial X-ray studies show signs of soft tissue swelling in addition to boney erosion around the affected joint.<xref ref-type="bibr" rid="article-27216.r9">[9]</xref> MRI imagining is the most sensitive imagining study. Classically, MRI demonstrates joint effusion, hemosiderin deposits, expansion of the synovium, and boney erosion. Routine blood markers for inflammation, including erythrocyte sedimentation rate and C reactive protein, are not elevated in the majority of patients,&#x000a0;despite the clinical appearance of soft tissue swelling.<xref ref-type="bibr" rid="article-27216.r6">[6]</xref><xref ref-type="bibr" rid="article-27216.r4">[4]</xref> Several authors have suggested a link between a prior joint injury and the development of PVNS, but this correlation has not been proven to be consistent across investigators.<xref ref-type="bibr" rid="article-27216.r9">[9]</xref><xref ref-type="bibr" rid="article-27216.r13">[13]</xref> Incidental hemarthrosis from aspiration of a chronically inflamed joint can also provide an important diagnostic clue.<xref ref-type="bibr" rid="article-27216.r8">[8]</xref></p>
      </sec>
      <sec id="article-27216.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The gold standard of treatment for pigmented villonodular synovitis has traditionally been surgical excision with total synovectomy of the affected joint, either with an open or arthroscopic approach.<xref ref-type="bibr" rid="article-27216.r14">[14]</xref> While both of these methods have a similar reoccurrence rate of PVNS post-surgery, the arthroscopic procedure has consistently demonstrated better functional and range of motion outcomes for the patient.<xref ref-type="bibr" rid="article-27216.r15">[15]</xref> However, even after surgery, PVNS has a recurrence rate of up to 50%, prompting investigators to explore additional treatment options.<xref ref-type="bibr" rid="article-27216.r6">[6]</xref> When used as monotherapy, external beam radiation has demonstrated local control of up to 95.1% when dosed from 30 Gy to 50 Gy.<xref ref-type="bibr" rid="article-27216.r16">[16]</xref> Radiation therapy has also been shown to reduce PVNS recurrence post-surgical synovectomy significantly.<xref ref-type="bibr" rid="article-27216.r16">[16]</xref> The elucidation of the CSF-1 pathway has lead to the investigation of multiple systemic therapies, including monoclonal antibodies and tyrosine kinase inhibitors.&#x000a0; Amongst these agents, emactuzumab&#x000a0;and&#x000a0;PLX3397&#x000a0;show promise.<xref ref-type="bibr" rid="article-27216.r6">[6]</xref> Emactuzumab is a monoclonal antibody that directly binds the CSF-1 receptor on the surface of macrophages, thus reducing or eliminating the effects of aberrant CSF-1 production. In a recent phase 1 trial, 26 out of 28 patients with PVNS had an objective response to treatment with emactuzumab.<xref ref-type="bibr" rid="article-27216.r6">[6]</xref> PLX3397, which works by blocking molecular endpoints of CSF-1, demonstrated not only a well-tolerated side effect profile but also a clinical response in 52% of patients.<xref ref-type="bibr" rid="article-27216.r6">[6]</xref> Most recently, the use of pexidartinib,&#x000a0;a CSF-1 receptor antagonist, was approved by the FDA in August 2019 for use in patients with extensive disease who are not likely to benefit from surgical intervention.<xref ref-type="bibr" rid="article-27216.r17">[17]</xref></p>
      </sec>
      <sec id="article-27216.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Rheumatoid arthritis, septic joints, hemarthrosis, and other neoplasia can all mimic the clinical features of pigmented villonodular synovitis upon clinical inspection.<xref ref-type="bibr" rid="article-27216.r7">[7]</xref> Even with ideal radiographic and diagnostic studies, pigmented villonodular synovitis can get misdiagnosed as a ganglion, schwannoma, or hemangioma.<xref ref-type="bibr" rid="article-27216.r18">[18]</xref></p>
      </sec>
      <sec id="article-27216.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Pigmented villonodular synovitis demonstrates a locally destructive process but is rarely fatal. PVNS is primarily a disease of quality of life as it can lead to difficulty with activities of daily living and an overall decrease in quality of life.<xref ref-type="bibr" rid="article-27216.r6">[6]</xref></p>
      </sec>
      <sec id="article-27216.s11" sec-type="Complications">
        <title>Complications</title>
        <p>If left untreated, the complications of pigmented villonodular synovitis include moderate to severe joint deformity, degenerative articular changes, and osteoarthritis.<xref ref-type="bibr" rid="article-27216.r14">[14]</xref> If arthritic changes&#x000a0;produce severe erosion of articular surfaces, the ensuing cortical bone destruction can lead to the need for arthrodesis or amputation.<xref ref-type="bibr" rid="article-27216.r3">[3]</xref> Additional complications of PVNS are related to the interventions themselves.&#x000a0;Systemic treatment with&#x000a0;pexidartinib carries the primary risk factor of hepatic toxicity with close monitoring of liver enzymes being a critical aspect of management.<xref ref-type="bibr" rid="article-27216.r3">[3]</xref> Complications from surgery&#x000a0;depend on whether the clinician pursues an arthroscopic or open approach. Open surgeries correlate with more extended hospital stays and prolonged rehabilitation. Arthroscopic surgeries require technical expertise and may not be able to remove large masses with local tissue invasion.<xref ref-type="bibr" rid="article-27216.r16">[16]</xref> Metastasis of PVNS, both malignant and benign, is extremely rare.&#x000a0; However, there have been documented cases of metastasis to the lung, muscles, and lymph nodes.<xref ref-type="bibr" rid="article-27216.r19">[19]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-27216.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients need to be informed of both surgical and systemic treatments for pigmented villonodular synovitis so that they can make the most informed decision. If surgery is elected, the surgeon should discuss the pros and cons of open versus arthroscopic knee surgery with the patient based on the operability of the tumor itself and the desired functional outcome. It is equally important to discuss the&#x000a0;risks of the surgery itself about the benefits. Also, the high recurrence rate of PVNS despite surgical interventions requires emphasis.&#x000a0;Since PVNS can mimic many other disease pathologies and often gets misdiagnosed, it may be necessary for patients to seek providers from multiple specialties to come up with the best diagnostic and treatment plan.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-27216.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The ideal outcome for a patient diagnosed with pigmented villonodular synovitis results from an analysis of patient goals, realistic functional outcomes, the decision for surgery or systemic treatment, and care coordination across multiple specialties, utilizing an interprofessional team approach. The recommendation is that establishing a diagnosis is optimally from the interprofessional collaborative effort of the primary care doctor, radiologists, pathologists, and rehab team.<xref ref-type="bibr" rid="article-27216.r20">[20]</xref><xref ref-type="bibr" rid="article-27216.r21">[21]</xref> [Level 2]&#x000a0; By ordering and reviewing the correct imagining studies and clinical picture, the care team can decide if the decision to further biopsy the lesion is needed. Once a diagnosis is determined, it is important to consider the functional outcome of surgery vs. systemic treatment.&#x000a0;The best approach for this is through a discussion of patient care goals and the risks and benefits of surgical vs. systemic intervention.&#x000a0;For example, in difficult cases of PVNS that will not be likely to improve with surgery, the care team should consider the use of pexidartinib in patients without major hepatic co-morbidities.<xref ref-type="bibr" rid="article-27216.r17">[17]</xref> The pharmacy should have involvement in medical treatment, verifying dosing, administration, and checking for drug interactions or other contraindications. Nursing staff with specialty training in orthopedics and surgery can assist the clinician before diagnosis, during treatment in both medical and surgical cases, and provide ongoing support, evaluation, and counsel following surgery or during medical management. If surgery is the chosen option, physical therapy is highly recommended to regain function and muscle strength. Pain control management should involve the pharmacist, and the patient is encouraged to maintain a healthy weight. All these disciplines collaborating in an interprofessional team paradigm, ensure the best possible patient outcomes, regardless of the management tact chosen. [Level 5]</p>
        <p>Increasing the role of the patient in constructing a collaborative treatment will not only be helpful to solidify patient compliance in pigmented villonodular synovitis but also across the spectrum of disease in general.&#x000a0; It is strongly advised to develop and continue a patient-physician collaboration from diagnosis through treatment and management of PVNS.<xref ref-type="bibr" rid="article-27216.r22">[22]</xref> [Level 2]</p>
      </sec>
      <sec id="article-27216.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27216&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27216">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/joint-muscle-and-bone/pigmented-villonodular-synovitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27216">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27216/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27216">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-27216.s15">
        <fig id="article-27216.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Frontal view of the knees in this patient with right sided knee pain and swelling. There are erosions with high diffuse soft tissue swelling in the right knee and associated arthritic changes due to pigmented villonodular synovitis (PVNS). Contributed by Kevin Carter, DO</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="img001" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27216.s16">
        <fig id="article-27216.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Lateral view of the knee in this patient with swelling, demonstrating erosions, a large high density joint effusion suggestive of pigmented villonodular synovitis (PVNS). Contributed by Kevin Carter, DO</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="img004" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27216.s17">
        <fig id="article-27216.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Coronal CT image in a patient with knee swelling demonstrating erosions and a joint effusion due to pgimented villonodular synovitis (PVNS). Contributed by Kevin Carter, DO</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Coronal__CT" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27216.s18">
        <fig id="article-27216.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Villonodular synovitis Image courtesy O.Chaigasame</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Villonodular__synovitis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27216.s19">
        <fig id="article-27216.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Villonodular synovitis Image courtesy O.Chaigasame</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Villonodular__synovitis__hist" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-27216.s20">
        <title>References</title>
        <ref id="article-27216.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burton</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Bancroft</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Healey</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Burden of Illness Associated with Tenosynovial Giant Cell Tumors.</article-title>
            <source>Clin Ther</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>593</fpage>
            <page-range>593-602.e1</page-range>
            <pub-id pub-id-type="pmid">29580718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Staals</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Donati</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Palmerini</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives.</article-title>
            <source>Eur J Cancer</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>63</volume>
            <fpage>34</fpage>
            <page-range>34-40</page-range>
            <pub-id pub-id-type="pmid">27267143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>West</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Subramanian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaygusuz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marinelli</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>De Luca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Downs-Kelly</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Goldblum</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Corless</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Gilks</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>TO</given-names>
              </name>
              <name>
                <surname>Huntsman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>van de Rijn</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2006</year>
            <month>Jan</month>
            <day>17</day>
            <volume>103</volume>
            <issue>3</issue>
            <fpage>690</fpage>
            <page-range>690-5</page-range>
            <pub-id pub-id-type="pmid">16407111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xie</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>CX</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>ZY</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>RZ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Pigmented villonodular synovitis: a retrospective multicenter study of 237 cases.</article-title>
            <source>PLoS One</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>e0121451</fpage>
            <pub-id pub-id-type="pmid">25799575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mastboom</surname>
                <given-names>MJL</given-names>
              </name>
              <name>
                <surname>Verspoor</surname>
                <given-names>FGM</given-names>
              </name>
              <name>
                <surname>Verschoor</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Uittenbogaard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nemeth</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mastboom</surname>
                <given-names>WJB</given-names>
              </name>
              <name>
                <surname>Bov&#x000e9;e</surname>
                <given-names>JVMG</given-names>
              </name>
              <name>
                <surname>Dijkstra</surname>
                <given-names>PDS</given-names>
              </name>
              <name>
                <surname>Schreuder</surname>
                <given-names>HWB</given-names>
              </name>
              <name>
                <surname>Gelderblom</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Van de Sande</surname>
                <given-names>MAJ</given-names>
              </name>
              <collab>TGCT study group</collab>
            </person-group>
            <article-title>Higher incidence rates than previously known in tenosynovial giant cell tumors.</article-title>
            <source>Acta Orthop</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>88</volume>
            <issue>6</issue>
            <fpage>688</fpage>
            <page-range>688-694</page-range>
            <pub-id pub-id-type="pmid">28787222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brahmi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vinceneux</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cassier</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.</article-title>
            <source>Curr Treat Options Oncol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>10</fpage>
            <pub-id pub-id-type="pmid">26820289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hua</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mu</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Multifocal pigmented villonodular synovitis in a child: A case report.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>95</volume>
            <issue>33</issue>
            <fpage>e4572</fpage>
            <pub-id pub-id-type="pmid">27537585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frassica</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Bhimani</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Wenz</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pigmented villonodular synovitis of the hip and knee.</article-title>
            <source>Am Fam Physician</source>
            <year>1999</year>
            <month>Oct</month>
            <day>01</day>
            <volume>60</volume>
            <issue>5</issue>
            <fpage>1404</fpage>
            <page-range>1404-10; discussion 1415</page-range>
            <pub-id pub-id-type="pmid">10524485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al Farii</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Turcotte</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The surgical outcome and recurrence rate of tenosynovial giant cell tumor in the elbow: a literature review.</article-title>
            <source>J Shoulder Elbow Surg</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>28</volume>
            <issue>9</issue>
            <fpage>1835</fpage>
            <page-range>1835-1840</page-range>
            <pub-id pub-id-type="pmid">31447124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramesh</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shetty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bastawrous</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Pigmented villonodular synovitis of the knee in a patient on oral anticoagulation therapy: a case report.</article-title>
            <source>J Med Case Rep</source>
            <year>2009</year>
            <month>Nov</month>
            <day>13</day>
            <volume>3</volume>
            <fpage>121</fpage>
            <pub-id pub-id-type="pmid">20062764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Houdek</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Scorianz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wyles</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Trousdale</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Sim</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Taunton</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcome of knee arthroplasty in the setting of pigmented villonodular synovitis.</article-title>
            <source>Knee</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>851</fpage>
            <page-range>851-855</page-range>
            <pub-id pub-id-type="pmid">28552192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Willimon</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Schrader</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Perkins</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Arthroscopic Management of Pigmented Villonodular Synovitis of the Hip in Children and Adolescents.</article-title>
            <source>Orthop J Sports Med</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>2325967118763118</fpage>
            <pub-id pub-id-type="pmid">29594178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Myers</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Masi</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Pigmented villonodular synovitis and tenosynovitis: a clinical epidemiologic study of 166 cases and literature review.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>1980</year>
            <month>May</month>
            <volume>59</volume>
            <issue>3</issue>
            <fpage>223</fpage>
            <page-range>223-38</page-range>
            <pub-id pub-id-type="pmid">7412554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kosy</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Theodoropoulos</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Systematic Arthroscopic Treatment of Diffuse Pigmented Villonodular Synovitis in the Knee.</article-title>
            <source>Arthrosc Tech</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>e1547</fpage>
            <page-range>e1547-e1551</page-range>
            <pub-id pub-id-type="pmid">29354472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weng</surname>
                <given-names>XS</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Surgical treatment of diffuse pigmented villonodular synovitis of the knee.</article-title>
            <source>Zhongguo Yi Xue Ke Xue Yuan Xue Bao</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>234</fpage>
            <page-range>234-9</page-range>
            <pub-id pub-id-type="pmid">25936715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mollon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Busse</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Wunder</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Theodoropoulos</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The effect of surgical synovectomy and radiotherapy on the rate of recurrence of pigmented villonodular synovitis of the knee: an individual patient meta-analysis.</article-title>
            <source>Bone Joint J</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>97-B</volume>
            <issue>4</issue>
            <fpage>550</fpage>
            <page-range>550-7</page-range>
            <pub-id pub-id-type="pmid">25820897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tap</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Gelderblom</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Palmerini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Blay</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Alcindor</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ganjoo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n-Broto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Peterfy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Healey</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>van de Sande</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gelhorn</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Shuster</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yver</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Tong-Starksen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stacchiotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>AJ</given-names>
              </name>
              <collab>ENLIVEN investigators</collab>
            </person-group>
            <article-title>Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.</article-title>
            <source>Lancet</source>
            <year>2019</year>
            <month>Aug</month>
            <day>10</day>
            <volume>394</volume>
            <issue>10197</issue>
            <fpage>478</fpage>
            <page-range>478-487</page-range>
            <pub-id pub-id-type="pmid">31229240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x000c7;evik</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Kayahan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eceviz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>G&#x000fc;m&#x000fc;&#x0015f;ta&#x0015f;</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Tenosynovial giant cell tumor in the foot and ankle.</article-title>
            <source>Foot Ankle Surg</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>712</fpage>
            <page-range>712-716</page-range>
            <pub-id pub-id-type="pmid">31526689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>de Castro</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Hendzel</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Iwaz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Valeshabad</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Shokouh-Amiri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Histologically benign metastasizing tenosynovial giant cell tumor mimicking metastatic malignancy: A case report and review of literature.</article-title>
            <source>Radiol Case Rep</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>8</issue>
            <fpage>934</fpage>
            <page-range>934-940</page-range>
            <pub-id pub-id-type="pmid">31193787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zwarenstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reeves</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Interprofessional collaboration: effects of practice-based interventions on professional practice and healthcare outcomes.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2009</year>
            <month>Jul</month>
            <day>08</day>
            <issue>3</issue>
            <fpage>CD000072</fpage>
            <pub-id pub-id-type="pmid">19588316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cao</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bland</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Giri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Maken</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dinh</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Hidalgo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>HB</given-names>
              </name>
            </person-group>
            <article-title>Patient-Centered Structured Interdisciplinary Bedside Rounds in the Medical ICU.</article-title>
            <source>Crit Care Med</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <page-range>85-92</page-range>
            <pub-id pub-id-type="pmid">29088002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27216.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arbuthnott</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sharpe</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The effect of physician-patient collaboration on patient adherence in non-psychiatric medicine.</article-title>
            <source>Patient Educ Couns</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>77</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-7</page-range>
            <pub-id pub-id-type="pmid">19395222</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
